Skip to main content
Toxicological Research logoLink to Toxicological Research
. 2019 Oct 15;35(4):331–341. doi: 10.5487/TR.2019.35.4.331

Molecular Markers in Sex Differences in Cancer

Ji Yoon Shin 1, Hee Jin Jung 1, Aree Moon 1,
PMCID: PMC6791665  PMID: 31636844

Abstract

Cancer is one of the common causes of death with a high degree of mortality, worldwide. In many types of cancers, if not all, sex-biased disparities have been observed. In these cancers, an individual’s sex has been shown to be one of the crucial factors underlying the incidence and mortality of cancer. Accumulating evidence suggests that differentially expressed genes and proteins may contribute to sex-biased differences in male and female cancers. Therefore, identification of these molecular differences is important for early diagnosis of cancer, prediction of cancer prognosis, and determination of response to specific therapies. In the present review, we summarize the differentially expressed genes and proteins in several cancers including bladder, colorectal, liver, lung, and non-small cell lung cancers as well as renal clear cell carcinoma, and head and neck squamous cell carcinoma. The sex-biased molecular differences were identified via proteomics, genomics, and big data analysis. The identified molecules represent potential candidates as sex-specific cancer biomarkers. Our study provides molecular insights into the impact of sex on cancers, suggesting strategies for sex-biased therapy against certain types of cancers.

Keywords: Sex difference, Cancer, Sex hormone, Chemotherapy

INTRODUCTION

Cancer is one of the most common diseases with an extremely high mortality rate (1). Several types of cancer show sex-biased tendencies in mortality and incidence (24). Lung cancer shows the highest incidence and mortality in males, and ranks third in incidence and second in mortality among females (5). The incidence and mortality of liver cancer in males are significantly higher than in females (6). The incidence of bladder cancer is three-to four-fold higher in males than in females (7). However, females are diagnosed with more advanced disease and worse prognosis after treatment compared with males (8,9). Data obtained from Korea and Japan indicate that colorectal cancer is not only associated with the highest mortality in females over 65 years of age, but also has a significantly higher incidence and mortality rate in females than in males over the age of 65 years (1012). In renal clear cell carcinoma, the incidence rate was twice as common in males than in females, and males showed a lower survival rate (13). Studies investigating the role of gender and incidence or mortality in head and neck squamous cell carcinoma had no significant differences by sex (14).

Sex differences in cancer are presumably induced by sex hormones, especially estrogen (15). Sex hormones are known to modulate gene expression in many cancers (16). Sexually dimorphic expression of molecules (gene or protein) are referred to as ‘sex-biased’ (1719). Sex-biased disparities in responsiveness and side effects to anticancer drugs have also been observed (reviewed in 16). For instance, the clearance of 5-fluorouracil (FU) is higher in males than in females (20,21). Females treated with 5-FU showed higher levels of toxicity such as nausea, vomiting, alopecia and leukopenia than males (21,22). The influence of gender on drug metabolism may contribute at least in part, to the sex-specific differences in susceptibility to anticancer drugs (2327).

Mounting evidence suggests that genetic and molecular differences between male and female cancers may contribute to sex-biased disparities in mortality and incidence of cancers (28). For instance, male patients with lung adenocarcinoma showed 1.636-fold higher frequency of genetic alterations than female patients, and greater genetic alterations were related to worse overall survival in males (29). At the genetic/molecular level, gene polymorphism and differential expression have been recognized as key factors for sex-biased differences in cancer incidence between males and females (16). However, the molecular differences between male and female cancer patients have yet to be elucidated. A comprehensive characterization of sex-biased molecular differences in cancer patients was conducted by analyzing the high-throughput molecular data obtained from The Cancer Genome Atlas (TCGA) (18).

Proteomics/genomics is one of the most efficient approaches to study the expression of proteins and genes (30). Currently, big data analytics of patient information is widely used in molecular studies. In this review, we have summarized the genes and proteins associated with sex-dependent expression via approaches such as proteomics, genomics, and big data analytics in bladder, colorectal, liver, lung and non-small cell lung cancers, renal clear cell and neck squamous cell carcinoma. All these cancers except renal clear cell and head and neck squamous cell carcinoma show sex-biased incidence and mortality. This review facilitates the design of an efficient strategy for sex-specific cancer therapy.

BLADDER CANCER

The incidence of bladder cancer is four times higher in females than in males (31,32). Studies investigated the association between the risk of bladder cancer and hypomethylation of long interspersed nuclear element-1 (LINE-1) (33). The findings suggest a lower frequency of methylation of LINE-1 in females than in males. Hypomethylation of LINE-1 may be an effective biomarker for the risk of bladder cancer in females. The lowest degree of LINE-1 methylation in females indicates a 2.5-fold significantly higher risk of bladder cancer. In males, however, there was no correlation between hypomethylation of LINE-1 and risk of bladder cancer (33). Sex-biased molecules in bladder cancer are listed in Table 1.

Table 1.

Sex-biased molecular differences in cancers

Bladder cancer
Name Gender Method Reference Remarks
Male Female
LINE1 (Methylation) Quantitative Bisulfite Pyrosequencing 33 Hypomethylation of LINE1 in females indicates higher risk of bladder cancer.
No relation in male.
−: Low frequency of methylation related to bladder cancer
Colorectal cancer
Name Gender Method Reference Remarks
Male Female
ERα + Immunoblot assay 42 Significantly increased in tumor tissue than normal tissue of male.
No alteration in female.
ERβ −− Significantly decreased in tumor tissue of female than male.
K-ras (Point mutations) − (younger male) Sequence-specific Oligonucleotide probes 41 More frequent mutations in older male than older female.
+ (older male)
p16INK4a (Methylation) + Methylation-specific PCR analysis 44
TWIST1 + RT-PCR analysis 34
+: High expression/point mutation/methylation related to colorectal cancer
−: Low expression/point mutation related to colorectal cancer
−−: Very low expression/point mutation related to colorectal cancer
Head and neck squamous cell carcinoma
Name Gender Method Reference Remarks
Male Female
Claudin-7 + Big data analytics (TCGA) 17 Higher expression in male
Smad4
Bad + Higher expression in female
GSK-3-alpha-beta
HER2
MAPK
p38
PDCD4
Rictor
Src_pY416
YAP
+: High expression related to head and neck squamous cell carcinoma
Liver cancer
Name Gender Method Reference Remarks
Male Female
ATP6V0B + Oligonucleotide microarray 46 Higher expression in male
BLVRB
IFNAR1
MTHFD1
NNT
PRDX1
SMARCA2
SOD1
ZNF33B
HUM3BMCP Located in the Y chromosome
JARIDID
RPS4Y
CYP1A2 + Enzyme activity 5355 Higher activity in male
CYP2C16
CYP2D6
CDK6 + Oligonucleotide microarray 46 Higher expression in female
FGFR2
FLJ20489
FGFR3
HSHRTPSN
MFAP
polyA site
PRDX3
PROL2
RPS4X
ARSE + Oligonucleotide microarray 46 Located in the X chromosome
DDX3X
E1F1AX
USP9X
XIST
CYP3A4 + Enzyme activity 51 Higher activity in female
+: High expression related to liver cancer
Lung cancer and non-small cell lung cancer
Name Gender Method Reference Remarks
Male Female
sFAS + Proteomics (multiplex immunoassays and mass spectrometry) 57 Higher expression in male
MMP-9
PAI-1
CD40 + Higher expression in female
EGFR + Immunohistochemistry 56 May be related to a higher response to anticancer drugs in female patients
PTHrP 59 Significant predictor of survival for female
+: High expression related to lung cancer and non-small cell lung cancer
Renal clear cell carcinoma
Name Gender Method Reference Remarks
Male Female
AR + Big data analytics (TCGA) 17 Higher expression in male
ARHJ
IRS1
JAB1
PAI-1
PKC-alpha
Transglutaminase
VEGFR2
VHL
4E-BP1 + Higher expression in female
Akt
DJ-1
NDRG1
p38
PTEN
Src
VEGFR2
VHL
+ : High expression related to renal clear cell carcinoma

COLORECTAL CANCER

A comparison of 54 colorectal cancer biopsies and mRNAs of adjacent normal mucosal tissues by RT-PCR analysis revealed a significant overexpression of twist family basic helix-loop-helix transcription factor 1 (TWIST1) in colorectal cancer samples compared with benign colon mucosa and a significant increase in patients with nodal invasion (34). TWIST1 is involved in the regulation of epithelial-mesenchymal transition (EMT), inducing cancer progression and metastasis, in various cancers (3537). Notably, the expression of TWIST1 mRNA was higher in males than in females, suggesting the possibility of differential transcriptional regulation of TWIST1 by sex hormones (34).

In early stage of colorectal carcinogenesis, KRAS mutations were observed in 27–43% of patients (3840). DNA from 251 primary tumors of Norwegian patients with colorectal carcinoma was analyzed using sequence-specific oligonucleotide probes for the presence of k-ras point mutations at codons 12 and 13 (41). Male patients younger than 40 years carried fewer k-ras mutations in colon tumors compared with female patients (41). This finding suggested dominance of ras-independent pathways of colon cancer in younger males (41). In contrast, older males carried a higher number of k-ras mutations than older females (41).

The expression of ERα and ERβ protein showed no sex differences between normal colon mucosal tissues; however, significant differences were observed between tumor tissues (42). The ERα protein expression was significantly increased in tumor tissues of male patients compared with normal tissues (42). By contrast, the ERα level did not differ between tumor tissues and normal tissues of female patients (42). The level of ERβ protein and mRNA was significantly reduced in both male and female patients diagnosed with colon cancer, although a greater decrease was observed in males (42,43). The ERβ level was decreased in poorly differentiated tumors of males (42).

Colorectal cancer associated with the proximal colon in females may show a different disease subtype (44). In 120 sporadic colorectal cancers, methylation-specific PCR was performed to determine whether the methylation of the CpG island in the 5′ region of the p16INK4a tumor suppressor gene was associated with sex or other clinicopathological characteristics. In female patients, methylation-positive cancer was 8.8-fold higher than in male patients, and methylation of p16INK4a was associated with poorly differentiated tumors. Female patients with p16INK4a methylation may represent an important database of molecular alterations associated with sporadic colorectal cancers (44). Sex-biased molecular differences in colorectal cancer are listed in Table 1.

HEAD AND NECK SQUAMOUS CELL CARCINOMA

Abundant signals associated with sex-biased protein expression in head and neck squamous cell carcinoma were detected via TCGA database analysis (18). In patients with head and neck squamous cell carcinoma, 12 of 15 sex-biased proteins were identified, and the expression of Yes associated protein (YAP), programmed cell death 4 (PDCD4), glycogen synthase kinase 3 (GSK3-α/β), mitogen-activated protein kinase (MAPK), Src, p38, human epidermal growth factor receptor 2 (HER2), B cell leukemia/lymphoma (BCL2) associated agonist of cell death (Bad), and Rictor were upregulated in females whereas Claudin-7 and Smad4 were upregulated in males (18). SRC plays an important role in regulating a variety of cellular signal transduction pathways. The SRC kinase pathways are frequently activated in many carcinomas, especially metastatic diseases (45). In head and neck squamous cell carcinoma, SRC kinase may be the key molecule that shows a potential to be a female-specific prognosis marker. Sex-biased molecular differences in head and neck squamous cell carcinoma are listed in Table 1.

LIVER CANCER

In hepatocellular carcinoma, 27 genes were identified from male (n = 34) and female (n = 16) hepatocellular carcinoma patient tissue mRNAs, which showed sex-specific differential expression (46). Among these genes, 12 showed higher and 15 lower levels of expression in males compared with females. Among the 12 genes expressed higher in male samples, interferon (α and β) receptor 1 (IFNAR1), ATPase H+ transporting V0 subunit b (ATP6V0B), biliverdin reductase B (BLVRB), zinc finger protein 33B (ZNF33B), nicotinamide nucleotide transhydrogenase (NNT), methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 (MTHFD1), superoxide dismutase 1 (SOD1), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2) and peroxide peroxidase 1 (PRDX1) were located on the autosome while ribosomal protein S4 Y-linked 1 (RPS4Y), lysine demethylase 5D (JARIDID), and HUM3BMCP were located on the Y chromosome. PRDX1 and SOD1 were highly expressed in male hepatocellular carcinoma samples (46). In hepatocellular carcinoma, PRDX1 may be a key molecule for sex-biased mortality and incidence. PRDX, a major component of antioxidant enzymes, removes reactive oxygen species (47). PRDX1 is a versatile molecule that regulates cell growth, differentiation, cell death and tumor suppression (48,49). However, the 15 genes with a higher expression in female samples include cyclin dependent kinase 6 (CDK6), PROL2, FLJ20489, fibroblast growth factor receptor 2 (FGFR2), microfibrillar-associated protein 2 (MFAP), peroxiredoxin 3 (PRDX3), fibroblast growth factor receptor 3 (FGFR3), polyA site, and HSHRTPSN located on the autosome, and inactive X specific transcripts (XIST), ubiquitin specific peptidase 9 X-linked (USP9X), E1F1AX, ribosomal protein S4 X-linked (RPS4X), arylsulfatase E (ARSE), and DEAD-box helicase 3 X-linked (DDX3X) on the X chromosome (46).

Sex differences in the gene expression of drug metabolizing enzymes and transporters result in differences in drug absorption, distribution, metabolism and excretion, possibly affecting drug efficacy and adverse reactions (50). Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) is an enzyme that is responsible for the metabolism of over 50% of all therapeutic drugs (51,52). Higher CYP3A4 activity was observed in females than in males; by contrast, higher activities of cytochrome P450 family 1 subfamily A member 2 (CYP1A2), cytochrome P450 2C16 (CYP2C16), cytochrome P450 family 2 subfamily D member 6 (CYP2D6) and cytochrome P450 family 2 subfamily E member 1 (CYP2E1) were detected in males than in females (5355). The analysis of enzymatic activity in human liver microsomes and hepatocytes revealed no significant differences in hepatic CYP3A4 activity between males and females (50). However, in primary hepatocytes, a two-fold higher activity of CYP3A4 was observed in females than in males (51). Sex-biased molecular differences in liver cancer are listed in Table 1.

LUNG CANCER AND NON-SMALL CELL LUNG CANCER

Epidermal growth factor receptor (EGFR), the most important therapeutic target in lung cancer, was specifically expressed in females (18). Erlotinib and gefitinib are the major anti-cancer drugs that target EGFR pathway in lung cancer (56). Female patients showed higher response to erlotinib than male patients (56). This higher response among female patients may be related to a higher expression of EGFR observed in females (18,56).

Sex-specific biomarkers were identified in non-small cell lung cancer, using multiplex immunoassays and mass spectrometry (57). In males, soluble Fas (sFAS), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1) were strongly predictive biomarkers, whereas soluble cluster of differentiation 40 (sCD40) was prognostic for cancers in females (57). The factors underlying these gender-biased differences in non-small cell lung cancer are not clear. Studies to date indicate that these proteins play different roles in male and female patients due to endocrine differences.

Parathyroid hormone-related protein (PTHrP) is upregulated in tumors with skeletal metastasis and commonly expressed in non-small cell lung carcinomas (58,59). Female patients diagnosed with non-small cell lung carcinoma with and without PTHrP showed a median survival of 55 and 22 months, respectively, whereas male survival was independent of PTHrP status for 38 months. PTHrP was suggested as a significant predictor of survival in female patients after adjusting for stage, age, and histology (59). Sex-biased molecular differences in lung cancer and non-small cell lung cancer are listed in Table 1.

RENAL CLEAR CELL CARCINOMA

Using TCGA database analytics, sex-biased proteins from renal clear cell carcinoma were analyzed (18). In renal clear cell carcinoma, 18 out of 25 proteins were upregulated in females. These include N-myc downstream regulated 1 (NDRG1), Akt, phosphatase and tensin homolog (PTEN), DJ-1, 4E binding protein 1 (4E-BP1), Src, and p38. The von Hippel-Lindau (VHL), phosphoribosylanthranilate isomerase 1 (PAI-1), PKC-alpha, VEGFR2, androgen receptor (AR), ARHJ, insulin receptor substrate 1 (IRS1), C-Jun activation domain-binding protein-1 (JAB1) genes were upregulated in males (18). Sex-biased molecular differences in renal clear cell carcinoma are listed in Table 1.

SEX-BIASED MOLECULES IN ANIMAL CANCERS

Large portions of genome in animals are shown to be sex-specific. Sex-biased gene expression may increase the differences between female and male development, to facilitate adaptive sex differentiation in vivo (6062). The genomic distribution of sex-biased genes (i.e., chromosomal binding patterns) in animals also provides clues to the evolutionary process and the underlying genetic variation in development according to sex (63,64). Mice and rats are frequently used for cancer research (65). In this review, we have summarized the sex-biased molecular differences in animal cancers.

Recently, a Hras12V transgenic mouse model was generated to demonstrate the development of male-biased hepatic tumorigenesis (66). The peritumor and tumoral tissues of male and female transgenic mice were compared with normal liver tissues of non-transgenic mice via proteomic analysis. During hepatic tumorigenesis, 19 proteins derived from males and 10 proteins from female mice showed sex-biased expression (66). The upregulated proteins in males were Rho GDP dissociation inhibitor alpha (ARHGDIA), fatty acid binding protein 1 (FABP1), nucleophosmin 1 (NPM1), ribosomal protein lateral stalk subunit P2 (RPLP2), dihydrodiol dehydrogenase (DHDH), ATP5D, farnesyl diphosphate synthase (FDPS), and ubiquilin 1 (UBQLN1). The proteins involved in DNA packing include Histone H4, Histone H2AA, and Histone H2AB. SFL2, protein disulfide isomerase family A member 6 (PDIA6), tropomyosin 1 (TPM1) were also upregulated in a male-specific manner (66). Female-specific proteins such as acyl-CoA oxidase 1 (ACOX1), adenosylhomocysteinase (AHCY), betaine-homocysteine S-methyltransferase 2 (BHMT2), glutathione S-transferase alpha 3 (GSTA3), basonuclin 2 (BNC2), calmodulin 1 (CALM1), and profiling 1 (PFN1) were downregulated (66). However, apolipoprotein A4 (APOA4), eukaryotic translation elongation factor 2 (Eef2), and heat shock protein family A member 8 (HSPA8) were upregulated in females. The metabolic category of proteins including aldehyde dehydrogenase 1 family member L1 (ALDH1L1), phosphoglycerate kinase 1 (PGK1), and sterol carrier protein 2 (SCP2) were downregulated in males. Glutathione peroxidase 1 (GPX1), peroxiredoxin 6 (PRDX6), cytochrome b5 type A (CYB5A), and heat shock protein family E member 1 (HSPE1) showed a reversal of expression in males and females (66).

To study the effects of forkhead box A1 (FOXA1), a member of the forkhead class of DNA-binding proteins, on liver cancer production, liver tumors were induced in female and male controls and liver-specific FOXA1/2-deficient mice (67). These hepatocyte nuclear factors are transcriptional activators of liver-specific transcripts such as albumin and transthyretin, and interact with chromatin as pioneering factors. After treatment with carcinogens, large and diverse tumors were detected in the females with FOXA1/2 deficiency, whereas tumor growth in male mutants was reduced compared with the control. Thus, the expression of FOXA-specific genes in mice seems to be related to the prognosis of hepatocellular carcinoma. It was suggested that FOXA1 and FOXA2 may promote hepatocellular carcinoma in male mice, while protecting female mice against hepatocellular carcinoma (67).

The expression of tumor suppressor genes (PTEN, p53 and Rb) was down-regulated in the early stages of female glycine N-methyltransferase (Gnmt)−/− mice, but not in male mice (65). The GNMT mediating 1-carbon metabolism affects DNA methylation by controlling the ratio of S-adenosylmethionine to S-adenosylmorphine (68,69). These data suggest that Gnmt deficiency not only increases the expression of tumor genes but also induces a decrease in the expression of other tumor suppressor genes in the early stages of tumorigenesis in female rats, which explains the higher risk of hepatocellular carcinoma in female Gnmt−/− mice (67). The sex-biased molecules are listed in Table 2.

Table 2.

Sex-biased molecules in animal liver cancers

Gene name Gender Method Reference Remarks
Male Female
ARHGDIA + Proteomics (2D-Fluorescence difference gel electrophoresis), genetics, and immunoblot assay 66 No significance in female
ATP5D
DHDH
FABP1
FDPS
Histone H2AA
Histone H2AB
Histone H4
NPM1
PDIA6
RPLP2
SFL2
TPM1
UBQLN1
FOXA1 + Chromatin Immunoprecipitation (ChIP) assays 67
FOXA2
p53 + Immunoblot assay, RT-PCR analysis, and microarray 68 Higher expression in male
Pten
Rb
APOA4 + Proteomics (2D-Fluorescence difference gel electrophoresis), genetics, and immunoblot assay 66 No significance in male
Eef2
HSPA8
ALDH1L1 No significance in female
PGK1
SCP2
ACOX1 No significance in male
AHCY
BHMT2
BNC2
CALM1
GSTA3
PFN1
+: High expression related to hepatocellular carcinomas in animals
−: low expression related to hepatocellular carcinomas in animals

CONCLUSIONS

We have summarized the molecules that are differentially expressed between males and females in bladder cancer, colorectal cancer, liver cancer, lung cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma and renal clear cell carcinoma. The sex-biased molecular differences in cancers are listed in Table 1 and 2. Molecular differences include sex-specific upregulation or downregulation of proteins and mRNAs, frequency of gene methylation, and activity of enzymes.

Sex-specific cancer therapies are indicated according to the differential role played by sex-biased molecular expression in oncology and pharmacology. Nevertheless, sex-specific follow-up clinical trials beyond sex hormone-specific therapy remain at an early stage (70). Many clinical and pre-clinical results suggest that sex and gender differences may affect drug-promoted pathological states such as drug digestion and drug dependence or addiction. Gender differences in drug pharmacodynamics and pharmacokinetics will also affect drug addiction, dependence and side effects (71,72). Efforts are needed to evaluate the clinical utility of sex-biased target therapies in a larger range of patient cohorts (70). There is still a lack of biologic relevance of cancer diagnosis, prognosis, severity, and prediction of response to treatment. Genomics studies showed a variation in the expression of autosomal genes between males and females (71). We believe that this variation may affect sex-specific cancer prognosis. Metabolomics studies also revealed gender differences in metabolite levels and their correlations with genetic markers (72).

Mechanisms underlying the differential expression of molecules in male and female cancers remain to be elucidated. Further investigation into the association of these molecules with sex-specific incidence and mortality of cancers is also needed. Our review elucidates the molecular differences to facilitate the identification of sex-specific cancer biomarkers.

ACKNOWLEDGMENTS

This study was supported by the Duksung Women’s University Research Grant 2018.

Footnotes

CONFLICT OF INTEREST

The authors have no conflict of interest to disclose.

REFERENCES

  • 1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. [DOI] [PubMed] [Google Scholar]
  • 2.Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011;20:1629–1637. doi: 10.1158/1055-9965.EPI-11-0246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. [DOI] [PubMed] [Google Scholar]
  • 4.Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjula C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das NJ, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet TM, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–548. doi: 10.1001/jamaoncol.2016.5688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
  • 6.Hefaiedh R, Ennaifer R, Romdhane H, Ben NH, Arfa N, Belhadj N, Gharbi L, Khalfallah T. Gender difference in patients with hepatocellular carcinoma. Tunis Med. 2013;91:505–508. [PubMed] [Google Scholar]
  • 7.Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69:300–310. doi: 10.1016/j.eururo.2015.08.037. [DOI] [PubMed] [Google Scholar]
  • 8.Horstmann M, Witthuhn R, Falk M, Stenzl A. Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med. 2008;5:385–394. doi: 10.1016/j.genm.2008.11.002. [DOI] [PubMed] [Google Scholar]
  • 9.Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010;105:300–308. doi: 10.1111/j.1464-410X.2009.09076.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–141. doi: 10.4143/crt.2015.060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2008;44:388–396. doi: 10.1093/jjco/hyu003. [DOI] [PubMed] [Google Scholar]
  • 12.Ferlay J, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–386. doi: 10.1002/ijc.29210. [DOI] [PubMed] [Google Scholar]
  • 13.Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008;179:1704–1708. doi: 10.1016/j.juro.2008.01.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Roberts JC, Li G, Reitzel LR, Wei Q, Sturgis EM. No evidence of sex-related survival disparities among head and neck cancer patients receiving similar multidisciplinary care: a matched-pair analysis. Clin Cancer Res. 2010;16:5019–5027. doi: 10.1158/1078-0432.CCR-10-0755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Özdemir BC, Dotto GP. Sex hormones and anticancer immunity. Clin Cancer Res. 2019 doi: 10.1158/1078-0432.CCR-19-0137. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 16.Kim HI, Lim H, Moon A. Sex differences in cancer: epidemiology, genetics and therapy. Biomol Ther (Seoul) 2018;26:335–342. doi: 10.4062/biomolther.2018.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cui C, Yang W, Shi J, Zhou Y, Yang J, Cui Q, Zhou Y. Identification and analysis of human sex-biased microRNAs. Genomics Proteomics Bioinformatics. 2018;16:200–211. doi: 10.1016/j.gpb.2018.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, Li J, Mills GB, Shu Y, Li L, Liang H. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29:711–722. doi: 10.1016/j.ccell.2016.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ellegren H, Parsch J. The evolution of sex-biased genes and sex-biased gene expression. Nat Rev Genet. 2007;8:689–698. doi: 10.1038/nrg2167. [DOI] [PubMed] [Google Scholar]
  • 20.Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171–1175. doi: 10.1200/JCO.1992.10.7.1171. [DOI] [PubMed] [Google Scholar]
  • 21.Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O’Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20:1491–1498. doi: 10.1200/JCO.2002.20.6.1491. [DOI] [PubMed] [Google Scholar]
  • 22.Lim H, Kim SY, Lee E, Lee S, Oh S, Jung J, Kim KS, Moon A. Sex-dependent adverse drug reactions to 5-fluorouracil in colorectal cancer. Biol Pharm Bull. 2019;42:594–600. doi: 10.1248/bpb.b18-00707. [DOI] [PubMed] [Google Scholar]
  • 23.Giudicelli JF, Tillement JP. Influence of sex on drug kinetics in man. Clin Pharmacokinet. 1977;2:157–166. doi: 10.2165/00003088-197702030-00001. [DOI] [PubMed] [Google Scholar]
  • 24.Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet. 1984;9:189–202. doi: 10.2165/00003088-198409030-00001. [DOI] [PubMed] [Google Scholar]
  • 25.Bonate PL. Gender-related differences in xenobiotic metabolism. J Clin Pharmacol. 1991;31:684–690. doi: 10.1002/j.1552-4604.1991.tb03760.x. [DOI] [PubMed] [Google Scholar]
  • 26.Harris JR, Tambs K, Magnus P. Sex-specific effects for body mass index in the new Norwegian twin panel. Genet Epidemiol. 1995;12:251–265. doi: 10.1002/gepi.1370120303. [DOI] [PubMed] [Google Scholar]
  • 27.Xie Y, Miller GG, Cubitt SA, Soderlind KJ, Allalunis-Turner MJ, Lown JW. Enediyne-lexitrop-sinDNA-targeted anticancer agents. Physicochemical and cytotoxic properties in human neoplastic cells in vitro, and intracellular distribution. Anticancer Drug Des. 1997;12:169–179. [PubMed] [Google Scholar]
  • 28.Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet. 2012;3:268–276. doi: 10.3389/fgene.2012.00268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Xiao D, Pan H, Li F, Wu K, Zhang X, He J. Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. Oncotarget. 2016;7:22857–22864. doi: 10.18632/oncotarget.8213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Baak JP, Path FR, Hermsen MA, Meijer G, Schmidt J, Janssen EA. Genomics and proteomics in cancer. Eur J Cancer. 2003;39:1199–1215. doi: 10.1016/S0959-8049(03)00265-X. [DOI] [PubMed] [Google Scholar]
  • 31.Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008;218:12–20. doi: 10.1080/03008880802285032. [DOI] [PubMed] [Google Scholar]
  • 32.American Cancer Society. Cancer Facts & Figures 2009. American Cancer Society; Atlanta: 2009. pp. 1–5. [Google Scholar]
  • 33.Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, Andrew AS, Morris S, Nelson HH, Schned AR, Karagas MR, Marsit CJ. Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res. 2010;16:1682–1689. doi: 10.1158/1078-0432.CCR-09-2983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Valdés-Mora F, Gómez del PT, Bandrés E, Cejas P, Ramírez de Molina A, Pérez-Palacios R, Gallego-Ortega D, García-Cabezas MA, Casado E, Larrauri J, Nistal M, González-Barón M, García-Foncillas J, Lacal JC. TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann Surg Oncol. 2009;16:78–87. doi: 10.1245/s10434-008-0166-x. [DOI] [PubMed] [Google Scholar]
  • 35.Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P, van Laere SJ, van Marck EA, Dirix LY, Vermeulen PB. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer. 2010;10:97. doi: 10.1186/1471-2407-10-97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K, Sakamoto A, Owaki T, Aikou T. Significance of Twist expression and its association with E-cadherin in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2009;28:158. doi: 10.1186/1756-9966-28-158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, Gonzalez-Herrero I, Sanchez-Garcia I, Silber JR, Horner PJ, Rostomily RC. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer. 2010;9:194. doi: 10.1186/1476-4598-9-194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–515. doi: 10.1093/annonc/mdm496. [DOI] [PubMed] [Google Scholar]
  • 39.Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995. doi: 10.1158/0008-5472.CAN-06-0191. [DOI] [PubMed] [Google Scholar]
  • 40.Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008;7:184–190. doi: 10.3816/CCC.2008.n.024. [DOI] [PubMed] [Google Scholar]
  • 41.Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer. 1994;69:367–371. doi: 10.1038/bjc.1994.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Nüssler NC, Reinbacher K, Shanny N, Schirmeier A, Glanemann M, Neuhaus P, Nussler AK, Kirschner M. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend Med. 2008;5:209–217. doi: 10.1016/j.genm.2008.07.005. [DOI] [PubMed] [Google Scholar]
  • 43.Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res. 2001;61:632–640. [PubMed] [Google Scholar]
  • 44.Wiencke JK, Zheng S, Lafuente A, Lafuente MJ, Grudzen C, Wrensch MR, Miike R, Ballesta A, Trias M. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:501–506. [PubMed] [Google Scholar]
  • 45.Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol. 2004;82:263–274. doi: 10.1139/o03-077. [DOI] [PubMed] [Google Scholar]
  • 46.Takemoto N, Iizuka N, Yamada-Okabe H, Hamada K, Tamesa T, Okada T, Hashimoto K, Sakamoto K, Takashima M, Miyamoto T, Uchimura S, Hamamoto Y, Oka M. Sex-based molecular profiling of hepatitis C virus-related hepatocellular carcinoma. Int J Oncol. 2005;26:673–678. [PubMed] [Google Scholar]
  • 47.Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W, Jia WD. Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. 2014;31:786–797. doi: 10.1007/s12032-013-0786-2. [DOI] [PubMed] [Google Scholar]
  • 48.Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, Säily M, Kinnula VL. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004;111:514–521. doi: 10.1002/ijc.20294. [DOI] [PubMed] [Google Scholar]
  • 49.Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res. 2009;28:93. doi: 10.1186/1756-9966-28-93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yang L, Li Y, Hong H, Chang CW, Guo LW, Lyn-Cook B, Shi L, Ning B. Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J Drug Metab Toxicol. 2012;3:1000119. doi: 10.4172/2157-7609.1000119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193–209. doi: 10.1016/j.taap.2004.01.010. [DOI] [PubMed] [Google Scholar]
  • 52.Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901–905. [PubMed] [Google Scholar]
  • 53.Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24:339–346. doi: 10.1046/j.1365-2710.1999.00246.x. [DOI] [PubMed] [Google Scholar]
  • 54.Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol. 2008;4:413–424. doi: 10.1517/17425255.4.4.413. [DOI] [PubMed] [Google Scholar]
  • 55.Ou-Yang DS, Huang SL, Wang W, Xie HG, Xu ZH, Shu Y, Zhou HH. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol. 2000;49:145–151. doi: 10.1046/j.1365-2125.2000.00128.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132. doi: 10.1056/NEJMoa050753. [DOI] [PubMed] [Google Scholar]
  • 57.Izbicka E, Streeper RT, Michalek JE, Louden CL, Diaz A, 3rd, Campos DR. Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics. 2012;9:27–35. [PubMed] [Google Scholar]
  • 58.Liao J, McCauley LK. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP) Cancer Metastasis Rev. 2006;25:559–571. doi: 10.1007/s10555-006-9033-z. [DOI] [PubMed] [Google Scholar]
  • 59.Hastings RH, Laux AM, Casillas A, Xu R, Lukas Z, Ernstrom K, Deftos LJ. Sex-specific survival advantage with parathyroid hormone-related protein in nonsmall cell lung carcinoma patients. Clin Cancer Res. 2006;12:499–506. doi: 10.1158/1078-0432.CCR-05-0930. [DOI] [PubMed] [Google Scholar]
  • 60.Parisi M, Nuttall R, Naiman D, Bouffard G, Malley J, Andrews J, Eastman S, Oliver B. Paucity of genes on the Drosophila X chromosome showing male-biased expression. Science. 2003;299:697–700. doi: 10.1126/science.1079190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Ellegren H, Parsch J. The evolution of sex-biased genes and sex-biased gene expression. Nat Rev Genet. 2007;8:689–698. doi: 10.1038/nrg2167. [DOI] [PubMed] [Google Scholar]
  • 62.Williams TM, Carroll SB. Genetic and molecular insights into the development and evolution of sexual dimorphism. Nat Rev Genet. 2009;10:797–804. doi: 10.1038/nrg2687. [DOI] [PubMed] [Google Scholar]
  • 63.Mank JE, Avise JC. Evolutionary diversity and turn-over of sex determination in teleost fishes. Sex Dev. 2009;3:60–67. doi: 10.1159/000223071. [DOI] [PubMed] [Google Scholar]
  • 64.Connallon T, Clark AG. Sex linkage, sex-specific selection, and the role of recombination in the evolution of sexually dimorphic gene expression. Evolution. 2010;64:3417–3442. doi: 10.1111/j.1558-5646.2010.01136.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG, Hogenesch JB. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA. 2002;99:4465–4470. doi: 10.1073/pnas.012025199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Rong Z, Fan T, Li H, Li J, Wang K, Wang X, Dong J, Chen J, Wang F, Wang J, Wang A. Differential proteomic analysis of gender-dependent hepatic tumorigenesis in Hras12V transgenic mice. Mol Cell Proteomics. 2017;16:1475–1490. doi: 10.1074/mcp.M116.065474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012;148:72–83. doi: 10.1016/j.cell.2011.11.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Liao YJ, Liu SP, Lee CM, Yen CH, Chuang PC, Chen CY, Tsai TF, Huang SF, Lee YH, Chen YM. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: Implications of the gender disparity in liver cancer susceptibility. Int J Cancer. 2009;124:816–826. doi: 10.1002/ijc.23979. [DOI] [PubMed] [Google Scholar]
  • 69.Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 2007;45:1306–1312. doi: 10.1002/hep.21650. [DOI] [PubMed] [Google Scholar]
  • 70.Cheng F. Gender dimorphism creates divergent cancer susceptibilities. Trends Cancer. 2016;2:325–326. doi: 10.1016/j.trecan.2016.06.001. [DOI] [PubMed] [Google Scholar]
  • 71.Van Nas A, Guhathakurta D, Wang SS, Yehya N, Horvath S, Zhang B, Ingram-Drake L, Chaudhuri G, Schadt EE, Drake TA, Arnold AP, Lusis AJ. Elucidating the role of gonadal hormones in sexually dimorphic gene coexpression networks. Endocrinology. 2009;150:1235–1249. doi: 10.1210/en.2008-0563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Mittelstrass K, Ried JS, Yu Z, Krumsiek J, Gieger C, Prehn C, Roemisch-Margl W, Polonikov A, Peters A, Theis FJ, Meitinger T, Kronenberg F, Weidinger S, Wichmann HE, Suhre K, Wang-Sattler R, Adamski J, Illig T. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet. 2011;7:e1002215. doi: 10.1371/journal.pgen.1002215. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Toxicological Research are provided here courtesy of Korean Society of Toxicology

RESOURCES